Subunit Vaccine Effective Against TB Disease Progression

Henrietta Brewer
October 30, 2019

Senior technical advisor at IAVI, Ann M Ginesberg said there are 14 other TB vaccine candidates in pipeline and that IAVI is working with at least two other companies.

On Wednesday, Vice-President Venkaiah Naidu will officially inaugurate the 50th Union World Conference on Lung Health. At present, Bacille Calmette-Guerin (BCG) vaccine, which was developed in 1921, is given to children to prevent the infection in many countries, including India, which reports the maximum number of TB cases every year. The Indian government has made the fight against TB a central priority and boldly pledged to end TB by 2025, five years before the globally agreed target.

Studies suggest that a vaccine targeted to adolescents and adults would be the strongest tool to cut levels of TB. It was conducted in tuberculosis-endemic regions, at 11 sites in Kenya, South Africa and Zambia (www.clinicaltrials.gov NCT01755598).

The subjects were followed for three years to see if they developed pulmonary TB disease, the most contagious form. This current analysis, they said, is the final efficacy and safety analyses following 3 years of follow-up.


The prior analysis had found a higher percentage of vaccine efficacy for participants age 25 and younger compared to those who were older than age 25.

"The candidate vaccine has an acceptable safety and reactogenicity profile..."

"We can not eliminate TB globally unless we end it in India", said Jamhoih Tonsing, Director, The Union's South East Asia Office, New Delhi.

"WHO will continue to support the development of the M72 vaccine and once the results are confirmed of this very exciting vaccine, we will support member states to adopt and implement it", said Gebreselassi.


Dr Thomas Breuer, Chief Medical Officer of GSK Vaccines, said: "These results demonstrate that for the first time in nearly a century, the global community potentially has a new tool to help provide protection against TB".

For the first time since the search for an elusive cure began, a vaccine with a high probability of treating Tuberculosis among adults was unveiled by a group of global researchers in the city on Tuesday. If successful, the vaccine could prevent millions of new TB cases and subsequent deaths all over the globe.

The existing Bacille-Calmette-Guerin (BCG) vaccine - licensed for humans in 1921 - is only proven to be effective for children under five for limited forms of tuberculosis, scientists said at an worldwide conference in Hyderabad. In a move that will boost the global campaign against tuberculosis (TB), the International Union Against Tuberculosis and Lung Disease, known as The Union, announced on Tuesday that scientists are close to developing a "game-changing" vaccine which will protect adults from the deadly infectious disease. "We can not end the TB emergency unless we dramatically scale up prevention in those parts of the world where we are treating it. The cost of inaction is more unnecessary suffering and death", concluded Dr Fujiwara.


Other reports by iNewsToday

FOLLOW OUR NEWSPAPER